Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 28 Sep 2016 Status changed from active, no longer recruiting to discontinued due Slow accrual.
- 29 Jul 2015 Planned End Date changed from 1 Oct 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 29 Jul 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.